High Cost Generics (HCG) Drug List

Total Page:16

File Type:pdf, Size:1020Kb

High Cost Generics (HCG) Drug List High Cost Generics (HCG) Drug List GlobalHealth, in partnership with MagellanRx, continually monitors generic medications to offer the best overall health care value at the lowest possible tier. A Generic Drug is equivalent to its brand name counterpart. While generic medications are usually less expensive than brand name medications, certain generics are not always the lowest cost option. There are times where a generic alternative can be more expensive than other generic medications within the same therapeutic class. We have identified options for members to reduce out-of-pocket costs, while offering the same clinical benefit. The following is the 2021 list of High Cost Generics. For additional questions on lower cost options please consult your primary care physician or contact Magellan at 1-800-424-1789. Please Note: High Cost Generics will process at Tier 3 copays. Drug Name Alternatives ACETAMN-CAF- ACETAMIN-CAF-DIHYDROCODEIN DIHYDRCODEIN 320.5 325 CAPSULE ALCLOMETASONE DIPR ALCLOMETASONE DIPRO 0.05% CRM 0.05% OINT BUTALBITAL- ALLZITAL 25-325 MG TABLET ACETAMINOPHN 50-325 ALMOTRIPTAN MALATE TAB NARATRIPTAN HCL sumatriptan zolmitriptan AMCINONIDE 0.1% CREAM aclometasone desonide AMCINONIDE 0.1% LOTION aclometasone desonide APREPITANT 125-80-80 MG PACK ondansetron Aprepitant capsule AVAR-E GREEN EMOLLIENT CREAM AVAR-E EMOLLIENT CREAM NEO-POLYCIN EYE BACITRACIN 500 UNIT/GM OPHTH GENTAMICIN 0.3% EYE DROP OINTMENT NEO-POLYCIN EYE BACITRACIN-POLYMYXIN EYE OINT GENTAMICIN 0.3% EYE DROP OINTMENT BENAZEPRIL-HCTZ TAB lisinopril/hydrochlorothiazide BENZONATATE CAPSULE OTC robitussin BENZTROPINE 2 MG/2 ML AMPULE trihexyphenidyl hcl Benztropine Vial BETAMETHASONE VALER 0.12% aclometasone desonide FOAM magellanrx.com 1 │ 2020. Magellan Rx Management, LLC. All rights reserved. MRX1305_1219 Drug Name Alternatives BIMATOPROST 0.03% EYE DROPS Latanoprost BIMATOPROST 0.03% EYELASH SOLN n/a BP 10-1 WASH AVAR-E EMOLLIENT CREAM BRIMONIDINE 0.2% EYE BRIMONIDINE TARTRATE 0.15% DRP DROP BROMFENAC SODIUM 0.09% EYE diclofenac flurbiprofen ketorolac DRP BROMOCRIPTINE 2.5 MG TABLET Carbidopa/Levodopa Benztropine BROMOCRIPTINE 5 MG CAPSULE Carbidopa/Levodopa Benztropine BUDESONIDE 0.25 MG/2 ML BUDESONIDE 0.5 MG/2 ML BUDESONIDE 1 MG/2 ML INH SUSP SUSP SUSP BUDESONIDE EC 3 MG CAPSULE prednisone BUMETANIDE TABLET torsemide furosemide Bumetanide 0.5mg BUTALBITAL- BUTALBITAL-ACETAMINOPHN 50-300 ACETAMINOPHEN 50-325 TABLET CAFFEINE CIT 60 MG/3 ML ORAL Butalbital/Caffiene/APAP CALCIPOTRIENE 0.005% CREAM CALCIPOTRIENE OINTMENT CALCIPOTRIENE SOLUTION TRIAMCINOLONE 0.025% CALCITRENE 0.005% OINTMENT OINT CALCIPOTRIENE 0.005% CALCIPOTRIENE 0.005% CALCITRIOL 3 MCG/G OINTMENT OINTMENT CREAM CAPTOPRIL TABLET Lisinopril CARBINOXAMINE MALEATE 6 MG CARBINOXAMINE MALEATE TAB 4 MG TAB CARISOPRODOL 250 MG TABLET Carisoprodol 350mg CARVEDILOL ER CAPSULE Carvedilol CERAMAX SKIN BARRIER CREAM OTC emollient CHLORZOXAZONE 500 MG CHLORZOXAZONE 250 MG TABLET TABLET CLINDAMYCIN PH 1% CLINDACIN ETZ 1% PLEDGET SOLUTION CLINDAMYCIN PH 1% CLINDACIN P 1% PLEDGETS SOLUTION CLINDAMYCIN PHOSPHATE 1% CLINDAMYCIN PH 1% FOAM SOLUTION CLINDA-TRETINOIN 1.2%-0.025% Clinda-Benzoyl Peroxide CLOBETASOL 0.05% TOPICAL LOTN aclometasone desonide CLOBETASOL EMOLLNT 0.05% FOAM aclometasone desonide CLOBETASOL EMULSION 0.05% aclometasone desonide FOAM CLOBETASOL PROP 0.05% FOAM aclometasone desonide CLOBETASOL PROP 0.05% SPRAY aclometasone desonide 2 │ 2020. Magellan Rx Management, LLC. All rights reserved. MRX1305_1219 Drug Name Alternatives CLOCORTOLONE 0.1% CREAM PUMP aclometasone desonide CLOCORTOLONE PIVALATE 0.1% CRM aclometasone desonide CLOBETASOL 0.05% CLODAN 0.05% SHAMPOO SHAMPOO CLONIDINE HCL ER 0.1 MG TABLET Clonidine CLONIDINE PATCH Clonidine Tablet CLOTRIMAZOLE-BETAMETHASONE CLOTRIMAZOLE- LOT BETAMETHASONE CREAM COLESTIPOL HCL 1 GM TABLET FENOFIBRATE 54 MG TABLET COLESTIPOL HCL GRANULES FENOFIBRATE 54 MG TABLET COLESTIPOL HCL GRANULES PACKET FENOFIBRATE 54 MG TABLET COLESTIPOL MICRONIZED 1 GM TAB FENOFIBRATE 54 MG TABLET CORTISONE 25 MG TABLET Hydrocortisone CVS OMEPRAZOLE-BICARB 20-1,100 Omeprazole CYCLOBENZAPRINE 10 MG CYCLOBENZAPRINE 7.5 MG TABLET TABLET CYCLOBENZAPRINE 10 MG CYCLOBENZAPRINE ER TABLET CARISOPRODOL 350 mg CYCLOBENZAPRINE 10 MG DANTROLENE SODIUM CAP tablet TABLET SODIUM SULFACETAMIDE CLINDAMYCIN-BENZOYL DAPSONE 5% GEL LOTION PEROXIDE GEL DESLORATADINE ODT FEXOFENADINE FEXOFENADINE OTC DESMOPRESSIN AC 4 MCG/ML VIAL Desmopressin Tablet DESOXIMETASONE 0.05% CREAM aclometasone desonide DESOXIMETASONE 0.05% OINTMENT aclometasone desonide DESVENLAFAXINE ER TAB desvenlafaxine fumarate DEXAMETHASONE 1.5 MG DEXAMETHASONE 10 DAY 1.5 MG TB TABLET DEXAMETHASONE 1.5 MG DEXAMETHASONE 13 DAY 1.5 MG TB TABLET DEXAMETHASONE 1.5 MG DEXAMETHASONE 6 DAY 1.5 MG TAB TABLET DEXCHLORPHENIRAMINE 2 MG/5 ML DICLOFENAC 1.5% TOPICAL SOLN Diclofenac 1% DICLOFENAC EPOLAMINE 1.3% PTCH ACETAMINOPHEN (OTC) THERMACARE (OTC) IBUPROFEN (OTC) DICLOFENAC SOD DR 50 MG DICLOFENAC SOD DR 25 MG TAB TAB FLUOROURACIL 5% TOPICAL DICLOFENAC SODIUM 3% GEL SOLN DIFLORASONE 0.05% CREAM aclometasone desonide DIFLORASONE 0.05% OINTMENT aclometasone desonide 3 │ 2020. Magellan Rx Management, LLC. All rights reserved. MRX1305_1219 Drug Name Alternatives DIGOXIN 0.05 MG/ML SOLUTION Digoxin Tablet DOXEPIN 5% CREAM OTC Anti-Itch cream Doxycycline Hyclate DOXYCYCLINE HYC DR TAB Doxycycline Hyclate 50mg 100mg Doxycycline Hyclate DOXYCYCLINE HYCLATE TAB Doxycycline Hyclate 50mg 100mg Doxycycline Monohydrate DOXYCYCLINE IR-DR 40 MG CAP Doxycycline Monohydrate 50mg 100mg Doxycycline Monohydrate DOXYCYCLINE MONO CAP Doxycycline Monohydrate 50mg 100mg Doxycycline Monohydrate DOXYCYCLINE MONO TABLET Doxycycline Monohydrate 50mg 100mg DROSP-EE-LEVOMEF 3-0.03- DROSP-EE-LEVOMEF 3-0.02-0.451 0.451 ENDOCET TABLET Oxycodone/APAP 5-325mg ENTACAPONE 200 MG TABLET Carbidopa/Levodopa/Entacapone EPLERENONE TABLET Spironolactone BUTALB-ACETAMIN-CAFF 50-325- ESGIC CAPSULE 40 ESOMEPRAZOLE DR 49.3 MG CAP LANSOPRAZOLE OMEPRAZOLE ESOMEPRAZOLE DR PACKET LANSOPRAZOLE OMEPRAZOLE ESTRADIOL TDS 0.075 MG/DAY Estradiol tablet Estradiol patches ESTRADIOL VALERATE VL Estradiol tablet Estradiol patches ETHACRYNIC ACID 25 MG TABLET torsemide furosemide ETODOLAC ER 500 MG TABLET ibuprofen naproxen FAMOTIDINE 20 MG/5 ML-NS FAMOTIDINE 20 MG PIGGYBACK SYR FAMOTIDINE 40 MG/5 ML SUSP Famotidine Tablet FENOFIBRATE 48 MG FENOFIBRATE 50 MG CAPSULE FENOFIBRATE 54 MG TABLET TABLET FENOFIBRATE CAPSULE Fenofibrate 134mg FENOFIBRATE TABLET Fenofibrate 134mg FENOPROFEN CAPSULE Ibuprofen FENTANYL 100 MCG/HR FENTANYL 25 MCG/HR FENTANYL 37.5 MCG/HR PATCH FENTANYL 12 MCG/HR PATCH PATCH PATCH FENTANYL 100 MCG/HR FENTANYL 25 MCG/HR FENTANYL 62.5 MCG/HR PATCH FENTANYL 12 MCG/HR PATCH PATCH PATCH FENTANYL CIT OTFC Morphine Oxycodone ER FLUOCINOLONE 0.01% SCALP OIL aclometasone desonide FLUOCINOLONE 0.01% SOLUTION aclometasone desonide FLUOCINOLONE 0.025% CREAM aclometasone desonide FLUOCINOLONE 0.025% OINTMENT aclometasone desonide FLUOCINOLONE OIL 0.01% EAR FLAC OTIC OIL 0.01% EAR DROP DRP FLUOCINONIDE 0.1% CREAM aclometasone desonide 4 │ 2020. Magellan Rx Management, LLC. All rights reserved. MRX1305_1219 Drug Name Alternatives FLUOXETINE DR 90 MG CAPSULE Fluoxetine Capsule FLUOXETINE HCL TABLET Fluoxetine Capsule FLURANDRENOLIDE 0.05% CREAM aclometasone desonide FLURANDRENOLIDE 0.05% LOTION aclometasone desonide FLURANDRENOLIDE 0.05% aclometasone desonide OINTMENT FLUTICASONE PROP 0.05% LOTION aclometasone desonide FLUVASTATIN ER 80 MG TABLET atorvastatin lovastatin pravastatin FLUVASTATIN SODIUM CAP atorvastatin lovastatin pravastatin FROVATRIPTAN SUCC 2.5 MG TAB naratriptan sumatriptan zolmitriptan GATIFLOXACIN 0.5% EYE DROPS Moxifloxacin GAVILYTE-N SOLUTION GAVILYTE-C SOLUTION LIDOCAINE HCL 2% JEL GLYDO 2% JELLY SYRINGE UROJET AC GRISEOFULVIN MICRO 500 MG TAB Terbinafine GRISEOFULVIN ULTRA TAB Terbinafine DEXAMETHASONE 1.5 MG HIDEX 6 DAY 1.5 MG TABLET TABLET HYDROCOD-CPM-PSEUDOEP 5-4- Hydrocodone OTC PSEUDOEPHEDRINE 60/5 HYDROCODONE-ACETAMIN 10-300 Hydrocodone/APAP 10-325 MG HYDROCODONE-ACETAMIN 5-300 Hydrocodone/APAP 5-325 MG HYDROCODONE-ACETAMIN 7.5-300 Hydrocodone/APAP 7.5-325 HYDROCODONE-ACETAMN 7.5- Hydrocodone/APAP 5-325mg 325/15 HYDROCODONE-HOMATROPINE 5- HYDROCODONE- 1.5 HOMATROPINE SOLN HYDROCODONE-IBUPROFEN 10-200 Hydrocodone/APAP HYDROCODONE-IBUPROFEN 5-200 Hydrocodone/APAP MG HYDROCORT BUTY 0.1% LIPID CRM Hydrocortisone Buty Lotion HYDROCORT BUTY 0.1% LIPO CREAM Hydrocortisone Buty Lotion HYDROCORTISONE 1% HYDROCORTISONE 1% ABSORBASE CREAM HYDROMORPHONE 1 MG/ML MORPHINE SULF 10 MG/5 SOLUTION ML SOLN MORPHINE SULF 10 MG/5 HYDROMORPHONE 5 MG/5 ML SOLN ML SOLN HYDROMORPHONE HCL ER TAB Morphine Oxycodone ER IMIQUIMOD 5% CREAM IMIQUIMOD 3.75% CREAM PUMP PACKET IODOQUINOL-HYDROCORT-ALOE GEL n/a KETOCONAZOLE 2% FOAM Ketoconazole Cream KETOPROFEN 50 MG CAPSULE ibuprofen naproxen KETOPROFEN ER 200 MG CAPSULE ibuprofen naproxen 5 │ 2020. Magellan Rx Management, LLC. All rights reserved. MRX1305_1219 Drug Name Alternatives LACTULOSE 10 GM PACKET lactulose solution LANTHANUM CARB 1,000 MG TB SEVELAMER CARBONATE CHW 800 MG TABLET LEVORPHANOL TABLET morphine LIDOCAINE HCL 2% JEL LIDOCAINE HCL 2% JELLY URO-JET UROJET AC LIDOCAINE HCL 3% LOTION LIDOCAINE 4% CREAM LIDOCAINE HCL 4% SOLUTION LIDOCAINE 4% CREAM LIDOCAINE-PRILOCAINE CREAM LIDOCAINE 4% CREAM LIDOCAINE-PRILOCAINE LIDOCAINE-TETRACAINE 7%-7% CRM CREAM LINDANE 1% SHAMPOO NIX Permethrin MALATHION 0.5% LOTION Permethrin NIX MECLOFENAMATE CAPSULE Allopurinol MEFENAMIC ACID 250 MG CAPSULE ibuprofen naproxen MELODETTA 24
Recommended publications
  • List of New Drugs Approved in India from 1991 to 2000
    LIST OF NEW DRUGS APPROVED IN INDIA FROM 1991 TO 2000 S. No Name of Drug Pharmacological action/ Date of Indication Approval 1 Ciprofloxacin 0.3% w/v Eye Indicated in the treatment of February-1991 Drops/Eye Ointment/Ear Drop external ocular infection of the eye. 2 Diclofenac Sodium 1gm Gel March-1991 3 i)Cefaclor Monohydrate Antibiotic- In respiratory April-1991 250mg/500mg Capsule. infections, ENT infection, UT ii)Cefaclor Monohydrate infections, Skin and skin 125mg/5ml & 250mg/5ml structure infections. Suspension. iii)Cefaclor Monohydrate 100mg/ml Drops. iv)Cefaclor 187mg/5ml Suspension (For paediatric use). 4 Sheep Pox Vaccine (For April-1991 Veterinary) 5 Omeprazole 10mg/20mg Short term treatment of April-1991 Enteric Coated Granules duodenal ulcer, gastric ulcer, Capsule reflux oesophagitis, management of Zollinger- Ellison syndrome. 6 i)Nefopam Hydrochloride Non narcotic analgesic- Acute April-1991 30mg Tablet. and chronic pain, including ii)Nefopam Hydrochloride post-operative pain, dental 20mg/ml Injection. pain, musculo-skeletal pain, acute traumatic pain and cancer pain. 7 Buparvaquone 5% w/v Indicated in the treatment of April-1991 Solution for Injection (For bovine theileriosis. Veterinary) 8 i)Kitotifen Fumerate 1mg Anti asthmatic drug- Indicated May-1991 Tablet in prophylactic treatment of ii)Kitotifen Fumerate Syrup bronchial asthma, symptomatic iii)Ketotifen Fumerate Nasal improvement of allergic Drops conditions including rhinitis and conjunctivitis. 9 i)Pefloxacin Mesylate Antibacterial- In the treatment May-1991 Dihydrate 400mg Film Coated of severe infection in adults Tablet caused by sensitive ii)Pefloxacin Mesylate microorganism (gram -ve Dihydrate 400mg/5ml Injection pathogens and staphylococci). iii)Pefloxacin Mesylate Dihydrate 400mg I.V Bottles of 100ml/200ml 10 Ofloxacin 100mg/50ml & Indicated in RTI, UTI, May-1991 200mg/100ml vial Infusion gynaecological infection, skin/soft lesion infection.
    [Show full text]
  • Softgels' Clear Advantages
    DEEPDIVE REPORT March 2019 naturalproductsinsider.com Softgels’ Clear Advantages Report brought to you by DEEPDIVE REPORT Softgels’ Clear Advantages Contents Market snapshot ..................................................................................... 3 Consumer appeal .................................................................................... 4 Softgel history .......................................................................................... 6 Advantages of softgels ........................................................................... 7 How softgels are made .......................................................................... 9 Softgel challenges and solutions .......................................................11 Oxidation ...........................................................................................11 Consumer experience .......................................................................12 Dietary considerations ......................................................................12 Shelf stability ....................................................................................14 Bioavailability ....................................................................................14 Innovative developments .....................................................................16 Copyright © 2019 Informa Exhibitions LLC. All rights reserved. The publisher reserves the right to accept or reject any advertising or editorial material. Advertisers, and/or their agents, assume the
    [Show full text]
  • Fixed Drug Eruption Due to a Cerumenolytic Ear Drop; Hydrogen Peroxide and Boric Acid: a Case Report
    ISSN: 2688-8238 DOI: 10.33552/OJOR.2020.04.000577 Online Journal of Otolaryngology and Rhinology Case Report Copyright © All rights are reserved by Akif İşlek Fixed Drug Eruption Due to A Cerumenolytic Ear Drop; Hydrogen Peroxide and Boric Acid: A Case Report Akif İşlek1* and Engin Karaaslan2 1Nusaybin State Hospital, Otolaryngology-Head & Neck Surgery Clinic, Mardin, Turkey 2Nusaybin State Hospital, Dermatology and Venereology, Mardin, Turkey *Corresponding author: Received Date: October 24, 2020 Published Date: November 03, 2020 Akif İşlek, Nusaybin State Hospital, Otolaryngology-Head & Neck Surgery Clinic, Mardin, Turkey. Abstract Treatment of earwax often involves the use of a wax softening agent (cerumenolytic) with or without antimicrobial agents to easily removing. Cerumenolytic agents used to remove and soften earwax areoil-based treatments, water-based treatments. Fixed drug eruption (FDE) is a well- defined, circular, hyperpigmented plaque that usually occurs on the trunk, hands mucosal surfaces, after a systemical application of drugs. In this report, a case with FDE developed after a cerumenolytic agent (hydrogen peroxide and boric acid in water). A definitive diagnosis was made with skin punch biopsy and FDE was treated with oral levocetirizine and topical mometasone. Introduction is a well-defined, circular, hyper pigmenting plaque that usually Cerumen production is a normal and protective process occurs on the genitals, lips, trunk, and hands and the diagnosis for the external ear canal (EAC), but impact of cerumen causes can be confirmed by histopathologic examination of a small punch symptoms such as hearing loss, itching, pain, tinnitus [1]. Cerumen biopsy specimen [5]. In this report, a case with FDE developed after impaction is defined as an accumulation of cerumen in the a cerumenolytic agent (hydrogen peroxide and boric acid in water) external ear [2].
    [Show full text]
  • Oral Drug Delivery: Formulation Selection Methods & Novel Delivery Technologies
    ORAL DRUG DELIVERY: FORMULATION SELECTION METHODS & NOVEL DELIVERY TECHNOLOGIES OUTSTANDING ISSUE SPONSOR www.ondrugdelivery.com “Oral Drug Delivery: Formulation Selection Approaches CONTENTS & Novel Delivery Technologies” This edition is one in the ONdrugDelivery series of pub- No Longer a Hit-or-Miss Proposition: lications from Frederick Furness Publishing. Each issue focuses on a specific topic within the field of drug deliv- Once-Daily Formulation for Drugs with ery, and is supported by industry leaders in that field. pH-Dependent Solubility Gopi Venkatesh, Director of R&D & Anthony Recupero, EDITORIAL CALENDAR 2011: Senior Director, Business Development June: Injectable Drug Delivery (Devices Focus) Aptalis Pharmaceutical Technologies 4-8 July: Injectable Drug Delivery (Formulations Focus) September: Prefilled Syringes A possible approach for the desire to innovate October: Oral Drug Delivery Brian Wang, CEO & Dr Junsang Park, CSO November: Pulmonary & Nasal Drug Delivery (OINDP) GL PharmTech 10-13 December: Delivering Biotherapeutics SUBSCRIPTIONS: COMPANY PROFILE - To arrange your FREE subscription (pdf or print) to Mayne Pharma International 14-15 ONdrugDelivery, contact: Guy Furness, Publisher From Powder to Pill: A Rational Approach to T: +44 (0) 1273 78 24 24 E: [email protected] Formulating for First-into-Man Studies Dr Robert Harris, Director, Early Development SPONSORSHIP/ADVERTISING: Molecular Profiles Ltd 16-19 To feature your company in ONdrugDelivery, contact: Guy Furness, Publisher LiquiTime* Oral Liquid
    [Show full text]
  • Oral Dosage Forms That Should Not Be Crushed Formulary-Specific List for VCMC and SPH
    Oral Dosage Forms That Should Not be Crushed Formulary-Specific List for VCMC and SPH Generic Brand Dosage Form(s) Reasons/Comments amoxicillin-clavulanate Augmentin XR Tablet Slow-release (b,h) aspirin Aspirin EC Caplet; Tablet Slow-release; Enteric-coated aspirin and dipyridamole Aggrenox XR Capsule Slow-release atazanavir Reyataz Capsule Note: an oral powder is available, see prescribing information for administration instructions atomoxetine Strattera Capsule Note: capsule contents can cause ocular irritation - Do not open capsules as contents are an ocular irritant benzonatate Tessalon Perles Capsule Note: swallow whole; local anesthesia of the oral mucosa; choking could occur - Capsules are liquid-filled “perles” - Do not alter (break, cut, chew) integrity of dosage form; local mucosal irritant and anesthetic bisacodyl Dulcolax Capsule; Tablet Enteric-coated (c) bosentan Tracleer Tablet Note: women who are, or may become, pregnant, should not handle crushed or broken tablets brivaracetam Briviact Tablet Film-coated (b) budesonide Entocort EC Capsule Enteric-coated (a) - Capsules contain enteric-coated granules in extended-release matrix; can open capsules but do not crush contents - Products are formulated to release active drug at mid- to late small intestine buPROPion Wellbutrin XL Tablet Slow-release - Do not crush extended-release tablets - Immediate-release tablet products may be film-coated March 2019 carvedilol phosphate Coreg CR Capsule Slow-release (a) (Note: may add contents of capsule to chilled, not warm, applesauce
    [Show full text]
  • DESONATE® (Desonide) Gel 0.05% for Topical Use Only • Systemic Absorption May Require Evaluation for HPA Axis Suppression Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------- WARNINGS AND PRECAUTIONS------------------------ These highlights do not include all the information needed to use • Topical corticosteroids can produce reversible hypothalamic pituitary DESONATE Gel safely and effectively. See full prescribing information adrenal (HPA) axis suppression, Cushing's syndrome and unmask latent for DESONATE Gel. diabetes. (5.1) DESONATE® (desonide) Gel 0.05% for topical use only • Systemic absorption may require evaluation for HPA axis suppression Initial U.S. Approval: 1972 (5.1). • Modify use should HPA axis suppression develop (5.1) ---------------------------- INDICATIONS AND USAGE--------------------------- • Potent corticosteroids, use on large areas, prolonged use or occlusive use may increase systemic absorption (5.1) DESONATE is a corticosteroid indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. (1) • Local adverse reactions may include atrophy, striae, irritation, acneiform eruptions, hypopigmentation, and allergic contact dermatitis and may be ---------------------- DOSAGE AND ADMINISTRATION----------------------- more likely with occlusive use or more potent corticosteroids. (5.2, 5.4, 6) • Apply as a thin layer to the affected areas two times daily and rub in • Children may be more susceptible to systemic toxicity when treated with gently. (2) topical corticosteroids. (5.1, 8.4) • Therapy should be discontinued when control is achieved. (2) • If no improvement is seen within 4 weeks, reassessment of diagnosis ------------------------------ ADVERSE REACTIONS------------------------------- may be necessary. (2) The most common adverse reactions (incidence ≥ 1%) are headache and • Should not be used with occlusive dressings. (2) application site burning. (6) • Treatment beyond 4 consecutive weeks is not recommended. (2) To report SUSPECTED ADVERSE REACTIONS, contact LEO Pharma • For topical use only.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • A Randomized and Observer Blinded Comparison of Continuous Femoral
    a & hesi C st lin e ic n a l A f R Möller. J Anesthe Clinic Res 2011, 4:1 o e l s e a Journal of Anesthesia & Clinical DOI: 10.4172/2155-6148.1000.277 a n r r c u h o J ISSN: 2155-6148 Research Case Report Open Access A Randomized and Observer Blinded Comparison of Continuous Femoral Block and Fascia Iliaca Compartment Block in Hip Replacement Surgery Thorsten Möller1,2, Sabine Benthaus2, Maria Huber2, Ingrid Bentrup2, Markus Schofer3, Leopold Eberhart2, Hinnerk Wulf2 and Astrid Morin2* 1Department of Anesthesiology and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany 2Department of Anesthesiology and Critical Care Medicine, Philipps-University Marburg, Marburg, Germany 3Department of Orthopedy and Rheumatology, Philipps-University Marburg, Marburg, Germany Abstract Background: Techniques, analgesic effects and functional outcome of continuous femoral nerve and fascia iliaca compartment blocks were compared in patients undergoing hip replacement surgery. Methods: 80 patients were enroled in this randomized and observer-blinded study. 40 patients received a femoral nerve catheter with a stimulating catheter (FEM group) and 40 patients a fascia iliaca compartment catheter (FIC group). Before surgery, the catheters were placed. 50 mL prilocaine 1% was administered and a continuous infusion of ropivacaine 0.2% was maintained for 24 hours. Postoperative pain management with non-steroidal anti- inflammatory agents was standardized during the first 24 hours. No bolus application of a local anesthetic was allowed during this period. Intravenous opioide PCA with piritramide (comparable with morphin) was provided for 24 hours, and the patients were instructed to titrate their pain below a level of visual analogue scale of 3.
    [Show full text]
  • Steroids Topical
    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
    [Show full text]
  • Continuous Pericapsular Nerve Group Block for Postoperative Pain
    Fujino et al. JA Clinical Reports (2021) 7:22 https://doi.org/10.1186/s40981-021-00423-1 CASE REPORT Open Access Continuous pericapsular nerve group block for postoperative pain management in total hip arthroplasty: report of two cases Takashi Fujino1* , Masahiko Odo1, Hisako Okada1, Shinji Takahashi2 and Toshihiro Kikuchi1 Abstract Background: Total hip arthroplasty (THA) is one of the surgical procedures associated with severe postoperative pain. Appropriate postoperative pain management is effective for promoting early ambulation and reducing the length of hospital stay. Effects of conventional pain management strategies, such as femoral nerve block and fascia iliaca block, are inadequate in some cases. Case presentation: THA was planned for 2 patients with osteoarthritis. In addition to general anesthesia, continuous pericapsular nerve group (PENG) block and lateral femoral cutaneous nerve (LFCN) block were performed for postoperative pain management. Numerical rating scale (NRS) scores measured at rest and upon movement were low at 2, 12, 24, and 48 h postoperatively, suggesting that the treatments were effective for managing postoperative pain. The Bromage score at postoperative days (POD) 1 and 2 was 0. Conclusion: Continuous PENG block and LFCN block were effective for postoperative pain management in patients who underwent THA. PENG block did not cause postoperative motor blockade. Keywords: Pericapsular nerve group (PENG) block, Continuous peripheral nerve block, Total hip arthroplasty, Peripheral nerve block Background reported that it was more effective for managing postop- Total hip arthroplasty (THA) is associated with signifi- erative pain associated with THA than conventional cant postoperative pain [1]. Opioids are typically used peripheral nerve blocks [6].
    [Show full text]
  • Capsule Robot: a Theranostic Approach
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) Volume 3 Issue 10 October 2019 Review Article Capsule Robot: A Theranostic Approach Pradnya Palekar Shanbhag*, Tejal Gawade, Prerna Patil and Priyanka Deshmukh Department of Pharmaceutics, Oriental College of Pharmacy, Sanpada, Navi Mumbai, Affiliated to University of Mumbai, India *Corresponding Author: Pradnya Palekar Shanbhag, Head and Professor, Department of Pharmaceutics, Oriental College of Pharmacy, Sanpada,Received: Navi September Mumbai, 11, Affiliated 2019 ; Published: to University September of Mumbai, 27, India. 2019 DOI: 10.31080/ASPS.2019.03.0407 Abstract Increasing development in healthcare systems and availability of efficient miniaturized components or systems that are economic has led to profound scope for research in many new fields. Capsule robot was one such fictional idea that turned into factual reality because of use of applicative miniaturized components. Initially capsule robots were developed for endoscopic applications. These travel inside the gastrointestinal tract and thus capture images of the gastrointestinal tract and related areas. Later, capsule robots were developed to be used as the unique tool to construct micron and sub-micron sized drug delivery systems for target delivery and treatment. This article highlights on various aspects of capsule robots in diagnosis and therapy of various disorders and diseases, togetherKeywords: called Capsule theranostic Robot; approachEndoscopy; in Diagnosis;drug delivery Therapy systems. Introduction The rising demand for non invasive methodology for diagnosis controlled manner, Drug Delivery System (DDS) capsule endoscopy was designed. There are quite a number of research studies using rine type capsules which travel inside the body were used for en Microelectromechanical Systems (MEMS) for evaluating the drug and treatment led to the invention of capsule robots.
    [Show full text]
  • Medical Review~ Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 21-978 MEDICAL REVIEW~ CLINICAL REVIEW Application Type NDA Submission Number 21-978 Submission Code 000 Letter Date November 18, 2005 Stamp Date November 28, 2005 PDUFA Goal Date September 21,2006 Reviewer Name Denise Cook, M.D. Review Completion Date 8/28/06 Established Name Desonide (Proposed) Trade Name .. Therapeutic Class Topical corticosteroid Applicant Connectics Priority Designatiop S Formulation Foam, 0.05% Dosing Regimen bid Indication F or the treatment of mild to moderate atopic dermatitis . Intended Population Age 3 months and above Clinical Review Denise Cook, M.D. NDA 21-978/ N-OOO _ loam, 0.05%/desonide foam, 0.05% Table of Contents 1 EXECUTIVE SUMMARy................................................................................................................................5 1.1 RECOMMENDATION ON REGULATORY ACTION ...........................................................................................5 1 .2 RECOMMENDATION ON POSTMARKETING ACTIONS. .............. ...... .... .... ........... ........ ..... ... ..... ...... ......... ........5 1.2. I Risk Management Activity................ ......... ..... ............... ..... ................... ........ ........ .... ....... ... ......... ........5 1.2.2 Required Phase 4 Commitments............................................................................................................5 1.2.3 Other Phase 4 Requests..........................................................................................................................5
    [Show full text]